Galapagos NV (GLPG)

Market Cap	1.86B
Revenue (ttm)	311.49M
Net Income (ttm)	-183.25M
Shares Out	65.84M
EPS (ttm)	-2.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,943
Open	27.96
Previous Close	28.07
Day's Range	27.84 - 28.04
52-Week Range	22.36 - 31.23
Beta	-0.01
Analysts	Sell
Price Target	25.33 (-9.57%)
Earnings Date	Jul 23, 2025

About GLPG

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2005
• Employees: 704
• Stock Exchange: NASDAQ
• Ticker Symbol: GLPG
• Website: https://www.glpg.com

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.

Financial numbers in EUR

Analyst Forecast

According to 4 analysts, the average rating for GLPG stock is "Sell." The 12-month stock price forecast is $25.33, which is a decrease of -9.57% from the latest price.

Price Target

$25.33

(-9.57% downside)

Analyst Consensus: Sell